NEW YORK STATE MEDICAID PREFERRED DRUG LIST
All non-preferred drugs in these classes require prior authorization
ANALGESICS Narcotics - Long Acting Narcotics - Long Acting ANTI-INFECTIVES Anti-Fungals Anti-Fungals Anti-Virals Anti-Virals HTTP://NE Cephalosporins - Third Generation Cephalosporins - Third Generation Fluoroquinolones Fluoroquinolones Hepatitis C Agents Hepatitis C Agents NYS PREFERRED DRUG PROGRAM
2 Non-preferred as of 8/28/07 CC Clinical Criteria (https://newyork.fhsc.com/downloads/providers/NYRx_PDP_clinical_criteria.pdf)
NEW YORK STATE MEDICAID PREFERRED DRUG LIST
All non-preferred drugs in these classes require prior authorization
CARDIOVASCULAR Angiotensin Converting Enzyme Angiotensin Converting Enzyme Inhibitors (ACEIs) Inhibitors (ACEIs) ACEIs + Calcium Channel Blockers ACEIs + Calcium Channel Blockers ACEIs + Diuretics ACEIs + Diuretics HTTP://NE Angiotensin Receptor Blockers (ARBs) Angiotensin Receptor Blockers (ARBs) ARBs + Diuretics ARBs + Diuretics Beta Blockers Beta Blockers NYS PREFERRED DRUG PROGRAM
2 Non-preferred as of 8/28/07 CC Clinical Criteria (https://newyork.fhsc.com/downloads/providers/NYRx_PDP_clinical_criteria.pdf)
NEW YORK STATE MEDICAID PREFERRED DRUG LIST
All non-preferred drugs in these classes require prior authorization
Beta Blockers + Diuretics Beta Blockers + Diuretics Calcium Channel Blockers (Dihydropyridine) Calcium Channel Blockers (Dihydropyridine) Cholesterol Absorption Inhibitors Cholesterol Absorption Inhibitors HTTP://NE HMG-CoA Reductase Inhibitors (Statins) HMG-CoA Reductase Inhibitors (Statins) Triglyceride Lowering Agents Triglyceride Lowering Agents CENTRAL NERVOUS SYSTEM Sedative Hypnotics / Sleep Agents Sedative Hypnotics / Sleep Agents NYS PREFERRED DRUG PROGRAM
2 Non-preferred as of 8/28/07 CC Clinical Criteria (https://newyork.fhsc.com/downloads/providers/NYRx_PDP_clinical_criteria.pdf)
NEW YORK STATE MEDICAID PREFERRED DRUG LIST
All non-preferred drugs in these classes require prior authorization
Serotonin Receptor Agonists (Triptans) Serotonin Receptor Agonists (Triptans) M V. ENDOCRINE AND METABOLIC AGENTS Bisphosphonates Bisphosphonates Calcitonins - Intranasal Calcitonins - Intranasal Thiazolidinediones (TZDs) Thiazolidinediones (TZDs) HTTP://NE GASTROINTESTINAL Anti-Emetics Anti-Emetics Proton Pump Inhibitors (PPIs) Proton Pump Inhibitors (PPIs) IMMUNOLOGIC AGENTS Immunomodulators - Injectable Immunomodulators - Injectable NYS PREFERRED DRUG PROGRAM Immunomodulators - Topical Immunomodulators - Topical
2 Non-preferred as of 8/28/07 CC Clinical Criteria (https://newyork.fhsc.com/downloads/providers/NYRx_PDP_clinical_criteria.pdf)
NEW YORK STATE MEDICAID PREFERRED DRUG LIST
All non-preferred drugs in these classes require prior authorization
VIII. OPHTHALMICS Antihistamines - Ophthalmic Antihistamines - Ophthalmic Fluoroquinolones - Ophthalmic Fluoroquinolones - Ophthalmic
Ciloxan ® (solution, ointment) Quixin ®
.FHSC IX. OTICS Fluoroquinolones - Otic Fluoroquinolones - Otic RENAL AND GENITOURINARY Phosphate Binders / Regulators Phosphate Binders / Regulators HTTP://NE RESPIRATORY Anticholinergics - Inhaled Anticholinergics - Inhaled Antihistamines - Second Generation
Allegra ® (tablet, capsule, suspension) fexofenadine
Beta2 Adrenergic Agents - Inhaled Long Beta2 Adrenergic Agents - Inhaled Long NYS PREFERRED DRUG PROGRAM
2 Non-preferred as of 8/28/07 CC Clinical Criteria (https://newyork.fhsc.com/downloads/providers/NYRx_PDP_clinical_criteria.pdf)
NEW YORK STATE MEDICAID PREFERRED DRUG LIST
All non-preferred drugs in these classes require prior authorization
Beta2 Adrenergic Agents - Inhaled Short Beta2 Adrenergic Agents – Inhaled Short Corticosteroids - Inhaled Corticosteroids - Intranasal Corticosteroids - Intranasal HTTP://NE Leukotriene Modifiers Leukotriene Modifiers NYS PREFERRED DRUG PROGRAM
2 Non-preferred as of 8/28/07 CC Clinical Criteria (https://newyork.fhsc.com/downloads/providers/NYRx_PDP_clinical_criteria.pdf)
LIFE SCIENCES PAPER MEMORANDUM 1 Tissues, cells & molecular studies and Life Systems SECTION A: QUESTION 1 1.1.1 C 1.1.2 D √√ 1.1.3 A √√ 1.1.4 A √√ 1.1.5 C √√ 1.2.4 bivalent or homologous chromosomes √ 1.2.5 amniocentesis 1.3.3 B √ 1.3.4 A √ 1.3.5 D √ 1.4.1 C,E, D, B, F, A √ mark each 1.4.2 crossing over increases variation √
Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1 Amy K. Licis, Alicia Vallorani, Feng Gao, Cynthia Chen, Jason Lenox, Kelvin A. Yamada, Stephen P. Duntley andThe online version of this article can be found at: can be found at: Journal of Child Neurology Additional services and information for ª The Author(s) 2013Reprints and permission:Amy K. Licis, M